Sara Demy was recently interviewed by Janelle R. Anderson on the Human Proof of Concept podcast during Biotech Showcase. Janelle is currently a Managing Partner at CTI Life Sciences Fund.
If Biotech Showcase is the farm team for JPM, then Sara Demy is the coach. She literally got high fives when her conference burst onto the scene in 2008. Since then, it has busted out of its first two locations and now boasts over 3,000 attendees, with 400 presenting companies and 1,000 investors. Listen as Sara explains the launch of Biotech Showcase.
In the discussion at the Trans-Pacific Health Sciences Dialogue meeting led by Grace Pan, a partner at Holland and Knight we heard from Dr. Judy Jarecki-Black is Global Head of the Intellectual Property Department at Merial, Inc., the Animal Health subsidiary of Sanofi-Aventis. And Fang Xie, Ph.D. is Of Counsel at international law firm Greenberg Traurig, LLP where she co‐leads the firm’s Biotechnology and Pharmaceutical Group.
Dr. Fang Xie and Dr. Judy Jarecki-Black enlightened the participants about what it takes to obtain a patent in China and the different types of patents. During that same talk they explained the challenges of bringing new vaccines to China.
Obtaining patent protection and bringing new drugs ...
On the second day of Biotech Showcase we examined what the biotech industry should expect from the Trump Administration with the help of our friends at Hogan Lovells. Over the course of the luncheon plenary and two afternoon workshops panelists discussed what lies ahead for the Affordable Care Act, the FDA and CMS.
Repeal or Replace?
When it comes to the fate of the signature program of the Obama Administration, the Affordable Care Act, our panelists were skeptical that the Trump team and the Republican Congress will be able to make good on their promise to repeal the Act and replace it with ‘something much better.’
Greg Simon, formerly Executive Director of the ...
The 15th Annual Trans-Pacific Health Sciences Dialogue was a meeting for biopharmaceutical industry executives and business development executives who wanted to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.
In a discussion led by Grace Pan, a partner at Holland and Knight we heard from Dr. Judy Jarecki-Black, who is Global Head of the Intellectual Property Department at Merial, Inc., the Animal Health subsidiary of Sanofi-Aventis. Also part of the discussion was Fang Xie, Ph.D., Of Counsel at international law firm Greenberg Traurig, LLP, where she co‐leads the firm’s Biotechnology and Pharmaceutical Group.
For those of us who have been making the rounds of the investor meetings in 2015, it’s not news to hear that biotech’s time has come – in fact it’s almost a cliché.
Are we in another biotech market bubble, or have things fundamentally changed? That’s been the lingering question. But now financial data is beginning to come to light that supports the position that we are in the midst of a sea change rather than a bubble.
Bruce Booth, one of our favorite VC’s and a thoughtful blogger on biotech finance, did an analysis of post IPO performance of the recent crop of newly public biopharma companies. He discerns that a ...
In 2014 the biopharmaceutical industry has surpassed virtually every financial benchmark imaginable. As the industry gets ready to gather in San Francisco next month, the question on everyone’s mind is, how long will it last?
Analysts are predicting 2015 will be another strong year for the sector even if it doesn’t outperform 2014. The optimists argue that the current market upswing isn’t a bubble, but a reflection of a fundamental change in the business model. Credit Suisse calls it a transition from Biotech 1.0 based on hopes and dreams to a Biotech 2.0 model where next gen blockbusters deliver on the promise.
But while commercial success brings a new sense of stability to biotech financial markets, it also brings new risks.
A backlash ...
Polaris Partners joins the parade of new biotech funds launched in 2014 with a $450M fund which exceeds $400M number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova, among others, who have launched funds of similar size in 2014. http://www.fiercebiotech.com/story/polaris-adds-450m-years-bonanza-new-biotech-funds/2014-11-24?utm_medium=nl&utm_source=internal
These new funds will bring a welcome surge of new private capital to innovative biotechs. How will it be deployed and will it be enough to sustain early-stage development at a time when drug development costs are soaring? Our Wednesday plenary panel at Biotech Showcase will discuss these topics and others as they contemplate the next five years of private investment in the biopharmaceutical industry.
The Japanese biopharmaceutical industry emerged as a global player in the 1990s followed more recently by South Korea. As PharmAsia recently noted (subscription required) now China is emerging as a major source of both patients and innovation. Following Japan’s lead, East Asian biopharma companies are looking to partner with Western firms to increase their global reach. At the same time, US pharmaceutical companies want and need access to customers and technology in major Asian markets.
We created the Trans-Pacific Health Sciences Dialogue meeting to bring together dealmakers and senior executives from both sides of the Pacific to discuss how best to accelerate and develop collaborations. The invitation-only event has a well-earned reputation as the best ...